C4X Discovery Holdings plc
https://www.c4xdiscovery.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From C4X Discovery Holdings plc
Coming Through On Precision Medicine – C4X Discovery’s IBD Test Breakthrough
“Proper medicine driven by data” is how C4X Discovery Holdings’ CEO Clive Dix sees the future now that his immuno-inflammation focused company has been able to identify IBD genetic response signatures in patients treated with vedolizumab.
Destiny Joins AIM Exodus In Bid To Stay Afloat
Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- C4X Discovery Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice